title: Pittsburgh compound B binding in poststroke dementia.
abstract: We hypothesize that Pittsburgh compound B (PIB) binding is common in poststroke dementia (PSD) and that cognitive decline may be faster in PIB positive patients. We performed PIB positron emission tomography (PET) among 17 subjects: 10 PSD patients, 4 Alzheimer's disease (AD) patients, and 3 healthy controls. We also compared the rate of change in mini-mental state examination (MMSE) between PIB positive and negative patients. We detected AD-like PIB binding in 4 PSD patients (40%), all the AD patients, and 1 healthy control. The global PIB retention standardized uptake value (SUV) at 35-45 min for PIB positive stroke patients was 1.67 (range 1.56-1.82), which was similar to the AD patients (1.65; range 1.46-1.88) and was lower than PIB negative patients (1.29, range 1.24-1.34). Mean annual MMSE decline for the 4 PIB positive patients was 2.9 and that for the 6 PIB negative patients was 1. This pilot study suggests that PIB PET is feasible for the evaluation of PSD and PIB binding may be common in PSD. Whether presence of PIB binding is associated with a more rapid cognitive decline in PSD requires further study to confirm.
authors.affiliation: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, China. vctmok@cuhk.edu.hk
authors.forename: Vincent
authors.initials: V
authors.lastname: Mok
authors.forename: Eric Yim Lung
authors.initials: EY
authors.lastname: Leung
authors.forename: Winnie
authors.initials: W
authors.lastname: Chu
authors.forename: Sirong
authors.initials: S
authors.lastname: Chen
authors.forename: Adrian
authors.initials: A
authors.lastname: Wong
authors.forename: Yunyun
authors.initials: Y
authors.lastname: Xiong
authors.forename: Wynnie
authors.initials: W
authors.lastname: Lam
authors.forename: Chi Lai
authors.initials: CL
authors.lastname: Ho
authors.forename: Ka Sing
authors.initials: KS
authors.lastname: Wong
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology; D000814:Aniline Compounds / Q000378:metabolism* / Q000493:pharmacokinetics; D001667:Binding, Competitive / Q000187:drug effects / Q000502:physiology; D015415:Biomarkers / Q000032:analysis / Q000378:metabolism; D001921:Brain / Q000098:blood supply / Q000378:metabolism / Q000503:physiopathology; D003072:Cognition Disorders / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology; D015140:Dementia, Vascular / Q000000981:diagnostic imaging* / Q000378:metabolism* / Q000503:physiopathology; D004185:Disability Evaluation; D005260:Female; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D010865:Pilot Projects; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D012720:Severity of Illness Index; D020521:Stroke / Q000150:complications / Q000000981:diagnostic imaging* / Q000378:metabolism*; D013844:Thiazoles / Q000378:metabolism* / Q000493:pharmacokinetics
chemical_list: C475519:2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; D000814:Aniline Compounds; D015415:Biomarkers; D013844:Thiazoles